These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23771052)

  • 1. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
    Sabatino MA; Geroni C; Ganzinelli M; Ceruti R; Broggini M
    Epigenetics; 2013 Jun; 8(6):656-65. PubMed ID: 23771052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
    Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
    Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
    Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
    Lorusso D; Mainenti S; Pietragalla A; Ferrandina G; Foco G; Masciullo V; Scambia G
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1939-46. PubMed ID: 19938904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
    Mavis CK; Morey Kinney SR; Foster BA; Karpf AR
    Prostate; 2009 Sep; 69(12):1312-24. PubMed ID: 19444856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of glutathione transferases in the mechanism of brostallicin activation.
    Pezzola S; Antonini G; Geroni C; Beria I; Colombo M; Broggini M; Marchini S; Mongelli N; Leboffe L; MacArthur R; Mozzi AF; Federici G; Caccuri AM
    Biochemistry; 2010 Jan; 49(1):226-35. PubMed ID: 19950984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brostallicin: a new concept in minor groove DNA binder development.
    Broggini M; Marchini S; Fontana E; Moneta D; Fowst C; Geroni C
    Anticancer Drugs; 2004 Jan; 15(1):1-6. PubMed ID: 15090736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
    Lin X; Asgari K; Putzi MJ; Gage WR; Yu X; Cornblatt BS; Kumar A; Piantadosi S; DeWeese TL; De Marzo AM; Nelson WG
    Cancer Res; 2001 Dec; 61(24):8611-6. PubMed ID: 11751372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
    Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
    Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
    Chiam K; Centenera MM; Butler LM; Tilley WD; Bianco-Miotto T
    PLoS One; 2011; 6(9):e25634. PubMed ID: 21980513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
    Singal R; van Wert J; Bashambu M
    Cancer Res; 2001 Jun; 61(12):4820-6. PubMed ID: 11406558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.
    Dote H; Cerna D; Burgan WE; Carter DJ; Cerra MA; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2005 Jun; 11(12):4571-9. PubMed ID: 15958643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
    Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
    Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
    J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
    Ten Tije AJ; Verweij J; Sparreboom A; Van Der Gaast A; Fowst C; Fiorentini F; Tursi J; Antonellini A; Mantel M; Hartman CM; Stoter G; Planting AS; De Jonge MJ
    Clin Cancer Res; 2003 Aug; 9(8):2957-64. PubMed ID: 12912942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.
    Guirouilh-Barbat J; Zhang YW; Pommier Y
    Mol Cancer Ther; 2009 Jul; 8(7):1985-94. PubMed ID: 19584235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    Kumar SR; Bryan JN; Esebua M; Amos-Landgraf J; May TJ
    BMC Cancer; 2017 Feb; 17(1):158. PubMed ID: 28235398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma.
    Jerónimo C; Usadel H; Henrique R; Oliveira J; Lopes C; Nelson WG; Sidransky D
    J Natl Cancer Inst; 2001 Nov; 93(22):1747-52. PubMed ID: 11717336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
    Lockhart AC; Howard M; Hande KR; Roth BJ; Berlin JD; Vreeland F; Campbell A; Fontana E; Fiorentini F; Fowst C; Paty VA; Lankford O; Rothenberg ML
    Clin Cancer Res; 2004 Jan; 10(2):468-75. PubMed ID: 14760067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.